Market Research Logo

Non-Invasive Cancer Diagnostics Market 2015-2030

Non-Invasive Cancer Diagnostics Market 2015-2030

Cancer is an extremely complex disease and medical science is still struggling to figure out the factors influencing the disease origin, propagation, spread (metastasis) and relapse. In addition to satisfying the unmet market need for advanced and efficient treatment interventions, cancer prevention, early detection and management is extremely important. The high cancer mortality rate is primarily due to delay in detection of the disease. Early diagnosis and screening makes it possible to cure the disease completely and/or increase survival rates. Over the years, various technological advances have helped medical professionals understand cancer better. Recent research in cancer biology has led to a lot of innovation in the development of a number of new diagnostic tools. These modern diagnostic techniques can help detect and classify cancer with increased accuracy and sensitivity.

It is also important to highlight that the cost of management and treatment of cancer is a growing concern considering its highly progressive and fatal nature. Performing a biopsy includes costs associated with the equipment, cost of the procedure itself, consultation fees, hospital fees, costs of analytical tests and those associated with post-operative care. To manage this financial burden, the introduction of novel non-invasive techniques, which are cost-effective and more accurate, has become an indispensable necessity.

There are several advanced approaches, which are non-invasive or minimally invasive in nature, and these outweigh the limitations posed by invasive diagnostic procedures. Specifically, liquid biopsy has emerged as a promising non-invasive cancer diagnostic tool for early detection as well as monitoring the disease’s progress. This technique of tracing the presence of circulating biomarkers in blood and other biological fluids of cancer patients is becoming increasingly popular in the medical fraternity. In addition to liquid biopsy, the market is gradually witnessing the emergence of several other non-invasive diagnostic technologies. These include techniques based on molecular imaging, advanced genomic and transcriptomic methods of detection of clinically significant biomarkers and identification of nucleosomal levels. All such non-invasive tests hold a significant promise to enhance the quality of patient care.

SCOPE OF THE REPORT
The ‘Non-Invasive Cancer Diagnostics Market, 2015-2030’ report provides an extensive study on liquid biopsy kits/assays that are either commercialised or under development for the diagnosis of different types of cancer. Liquid biopsy primarily focuses on the detection, isolation and characterisation of biomarkers from circulating tumour cells (CTCs), circulating tumour DNA (ctDNA) or exosomes present in biological fluids, which can be collected in a single blood draw. The market is characterised by the presence of several companies that have proprietary technologies/platforms for either isolation/enrichment/enumeration of CTCs or molecular characterisation/sequencing of the genetic material extracted from the CTCs/exosomes. Based on these platforms, a number of liquid biopsy kits and systems are being developed for non-invasive diagnosis, prognosis, patient and recurrence monitoring. It is important to stress that even though liquid biopsy has still not made a strong foothold in the field of oncology, it is likely to transform the cancer diagnostics market with many commercial success stories in the near future.

In addition to liquid biopsy, there are several other novel and promising non-invasive diagnostics being developed for the diagnosis and prognosis of cancer. However, these tests are only indicative of the disease and may require further validation through more robust diagnostic methods such as biopsy. These tests retrieve the test sample non-invasively and use innovative techniques to screen for the desired parameters indicative of the disease with a moderate level of accuracy. Some of these are designed to be used at home by the patient itself.

As companies continue to initiate and expand their research programs and platforms in this area, one of the key objectives outlined for this report is to understand the future potential of the market. This is done by analysing:
The global burden of cancer in terms of incidence and prevalence of different cancer indications across different geographies.
The overall landscape of liquid biopsies and other novel diagnostic tests with respect to the type of analysis (CTCs/ctNA/exosomes), test sample source (blood/urine/others) and indications.
The likely global evolution of the liquid biopsy market taking into account initial diagnosis, recurrence monitoring and patient monitoring.
Contribution of other novel diagnostic tests in the non-invasive cancer diagnostics market and the market opportunity of the key indications influencing the overall growth.

We have provided three market forecast scenarios for the time period 2015-2030. The conservative, base and optimistic scenarios represent three different tracks of industry evolution. Our opinions and insights, presented in this study, were influenced by discussions that we conducted with experts in this area. All actual figures have been sourced and analysed from publicly available information and discussions with industry experts. The figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS
1. We have identified over 50 liquid biopsy tests; some of these are commercialised and the rest are currently under development. Of these, 50% tests are based on the identification of disease biomarkers in ctDNA of the test sample. Nearly 37% of the tests are based on the enumeration/analysis of CTCs in the sample and the remaining 13% validate the presence of the disease from the information obtained from exosomes.

2. Several companies are developing systems and instruments to support the detection, isolation and characterisation of rare cells. Examples include (in no specific order) the Parsortix System by ANGLE, ScreenCell® Isolation Devices by ScreenCell, ApoStream™ System by ApoCell, ClearCell FX® System by Clearbridge BioMedics and iCellate® Instrument by iCellate Medical.

3. Firms have also taken initiatives and entered into collaborations to co-develop liquid biopsy companion diagnostic products; notable examples include collaborations between Tokai Pharmaceuticals and Qiagen, AstraZeneca and Qiagen, Sysmex Inostics and Bayer HealthCare.

4. In addition to liquid biopsy, we have identified close to 40 other non-invasive cancer diagnostics that are used for screening, diagnosis, prognosis and patient monitoring; these include techniques based on molecular imaging, advanced methods of detecting clinically significant biomarkers and identification of nucleosomal levels.

5. Primarily driven by liquid biopsy, the non-invasive cancer diagnostics market is anticipated to grow aggressively at a healthy annual growth rate of 44% between 2015 and 2030. Prostate cancer, breast cancer, colorectal cancer and lung cancer are likely to be the key indications which will drive the market; combined, these are expected to account for over 70% of the total liquid biopsy market in 2030.

RESEARCH METHODOLOGY
Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 presents an executive summary of the report. It offers a high level view on where the market for liquid biopsy and other novel non-invasive diagnostics is headed in the mid to long term.

Chapter 3 provides a general introduction to cancer statistics and burden of the disease worldwide. In this section, we have also highlighted the importance of early detection of the disease through diagnosis and asymptomatic screening. The chapter outlines the conventional invasive diagnostic tests, which are widely used for cancer diagnosis and prognosis.

Chapter 4 discusses in detail the need for non-invasive cancer diagnostics and their importance. We have highlighted the underlying concept of liquid biopsy and other non-invasive tests. In addition, we have mentioned the principle behind common imaging tests that are deployed in cancer diagnosis.

Chapter 5 provides a holistic view of the non-invasive cancer diagnostics landscape. It enlists the liquid biopsy tests, technologies and systems. In addition, it offers a list of other non-invasive tests. These lists include information on the developer, technology used by the product, test sample source and indication. We have also mapped the geographical presence of the enlisted non-invasive cancer diagnostics developers.

Chapter 6 offers a comprehensive discussion on liquid biopsy. We have talked about the emerging need for liquid biopsy highlighting its advantages and challenges. In addition, we have provided technology profiles and product profiles of several liquid biopsy products. The chapter also mentions the liquid biopsy companion diagnostics, which are being co-developed as part of strategic collaborations.

Chapter 7 provides an overview of the other novel non-invasive diagnostics used in oncology. It highlights the different imaging based diagnostic procedures, biomarker and nucleosome based diagnostics, skin lesion and breath based diagnostics. The diagnostic procedures discussed in this chapter are backed up by several examples.

Chapter 8 highlights the market forecast and sizing of the overall non-invasive cancer diagnostics market. This chapter discusses, in detail, the parameters likely to influence the evolution of liquid biopsy market. In addition, we have also presented the market share of other non-invasive diagnostic tests and an opportunity analysis for the key indications likely to have the maximum impact on the overall market.

Chapter 9 provides detailed company profiles of the leading players in the market involved in the development of liquid biopsy as well as other non-invasive tests. Amongst other details, each profile includes information such as the company overview, financial performance, product portfolio and recent collaborations.

Chapter 10 summarises the overall report. In this chapter, we list the key takeaways and provide our independent opinion based on the research and analysis described in previous chapters.

Chapter 11 is a collection of interview transcripts of the discussions that were held during the course of this study.

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 13 is an appendix, which provides the list of companies and organisations mentioned in the report.

LIST OF COMPANIES AND ORGANISATIONS

The following companies and organisations have been mentioned in this report.

A&G Pharmaceutical
Accelerate Brain Cancer Cure
Acousys Biodevices
Addario Lung Cancer Medical Institute
Admera Health
AdnaGen
Affymetrix
Agena Bioscience
Almac Group
America’s Choice Provider Network
American Lung Association
Angle plc
Anixa Diagnostics Corporation
ApoCell
ARUP Laboratories
Astellas Pharma
AstraZeneca
Astute Medical
Aviva Biosciences
Barts Cancer Institute
Bayer Healthcare
BC Cancer Agency
BGI Tech Solutions
Biocartis
Biocept
Biodesix
BioFluidica
bioMérieux
Biosense Medical
Biotype Diagnostics
BioView
Boreal Genomics
Brigham and Women's Hospital
Canopus Bioscience
Catholic Health Initiatives Center
Clarient
Clearbridge BioMedics
Clovis Oncology
CollabRx
Columbia University
Comprehensive Cancer Center
COPAN
Creatv MicroTech
Cubist Pharmaceuticals
Cynvenio Biosystems
CytoTrack
CytoLumina Technologies
Dana Farber Cancer Institute
Datar Generics
Denovo Sciences
DermTech
DiagnoCure
Diagnologix
Digene Corporation
Drug Response Dx
EKF Molecular Diagnostics
Eli Lilly
Epic Sciences
Epigenomics
European Medical Network for Translational Research in Ovarian Cancer
Exact Sciences
Exosome Diagnostics
Exosomics Siena
Fairview Health Services
FedMed
Flatiron Health
Fluxion Biosciences
Foundation Medicine
Fraunhofer Institute for Cell Therapy and Immunology
Genomic Health
Genoptix
Gensignia
GlaxoSmithKline
Guangdong Medical College
Guardant Health
Hain Lifescience
HansaBioMed
Healthscope Pathology
Hitachi High-Technologies
iCellate Medical
Illumina
Incyte Genomics
Inivata
Insight Genetics
Ipsen
Ironwood Pharmaceuticals
IVDiagnostics
Janssen Diagnostics
OHSU Knight Cancer Institute
Labcorp
London Health Sciences Centre
Louisiana State University
Massachusetts General Hospital
Mayo Clinic
Mayo Medical Laboratory Network
MD Anderson Cancer Center
MDx Health
Medical University of Vienna
MELA Sciences
Merck Serono
MiNDERA
MolecularMD
Molecular Pathology Laboratory Network
Natera
National Cancer Institute
NeoGenomics Laboratory
Novartis
Novigenix
Ortho Biotech Oncology Research & Development
Pacific Edge
Palex Medical
Pathway Genomics
PathQC
Personal Genome Diagnostics
Promega Corporation
Prostate Cancer Foundation
Qiagen
Quanterix
Quest Diagnostics
RainDance Technologies
Rarecells Diagnostics
RareCyte
Roche
Rosetta Genomics
Roswell Park Cancer Institute
Royal Philips Electronics
Rutgers New Jersey Medical School
SAIC-Frederick
Sarah Cannon Research Institute
ScheBo
ScreenCell
Siemens
Sequenom
Shimadzu
Shuwen Biotech
Signal Genetics
Signature Diagnostics
Silicon Biosystems
SIMSYS
Skyline Diagnostics
Southern California Permanente Medical Group
SRI International
StableBody Technologies
Stiefel Laboratories
Strand Life Sciences
Sysmex Inostics
Tan Tock Seng Hospital
Targeted Diagnostics & Therapeutics
Technion-Israel Institute of Technology
The Valld’Hebron Institute of Oncology
Thermo Fisher Scientific
Thomas Jefferson University
Tokai Pharmaceuticals
Transgenomic
Trovagene
Tumour Bank Ovarian Cancer Network
University of California
University of Dusseldorf
University of Michigan
University of Nijmegen
University of Southern California
University of Texas
Uppsala BIO
Vancouver Prostate Centre
Veolia Environnement
Veracyte
Veridex
Viatar CTC Solutions
Virginia Commonwealth University
Vitatex
VolitionRx


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Cancer Statistics and Burden of the Disease
3.3. Importance of Early Detection in Cancer
3.4. Detecting Cancer: Screening versus Diagnosis
3.5. Conventional Invasive Cancer Diagnostic Tests
3.5.1. Biopsy
3.5.2. Endoscopy
3.6. Need for Non-Invasive Approaches
4. CONCEPT OF NON-INVASIVE CANCER SCREENING AND DIAGNOSTICS
4.1. Chapter Overview
4.2. Diagnostic Imaging
4.2.1. Magnetic Resonance Imaging (MRI)
4.2.2. Mammography
4.2.3. Bone Scan
4.2.4. Computerised Tomography (CT) Scan
4.2.5. Integrated PET-CT Scan
4.2.6. Ultrasound
4.2.7. Barium Enema
4.3. Screening Assays
4.3.1. Pap Test and HPV Test
4.3.2. Tumour Marker Tests
4.3.3. Faecal Occult Blood Tests (FOBT)
4.3.4. Digital Rectal Exam (DRE)
4.3.5. MUGA Scan
4.4. Advanced Non-Invasive Approaches
4.4.1. Liquid Biopsy
4.4.2. Cytogenetic/Gene Expression Studies
4.4.3. Molecular Signature Based Non-Invasive Methods
4.4.4. Saliva-Based Oral Cancer Diagnostics
4.4.5. Vital Staining
4.4.6. Optical Biopsy
4.4.7. Other Techniques
5. MARKET OVERVIEW
5.1. Chapter Overview
5.2. Liquid Biopsy: Market Landscape
5.2.1. Liquid Biopsy: Distribution by Type of Analysis
5.2.2. Liquid Biopsy: Distribution by Sample Source
5.2.3. Liquid Biopsy: Distribution by Indication
5.2.4. Liquid Biopsy: Distribution by Region
5.3. Liquid Biopsy Technologies and Systems/Instruments
5.4. Other Non-Invasive Cancer Diagnostic Tests: Market Landscape
5.4.1. Other Non-Invasive Tests: Distribution by Sample Source
5.4.2. Other Non-Invasive Tests: Distribution by Indication
5.4.3. Other Non-Invasive Tests: Distribution by Region
6. LIQUID BIOPSY: DETAILED OUTLOOK
6.1. Chapter Overview
6.2. Non-Invasive Detection of Cancer over Biopsies
6.3. Circulating Biomarkers for Cancer
6.3.1. CTCs and ctcDNA
6.3.2. ctDNA
6.3.3. Exosomes
6.4. Liquid Biopsy Based Technology, Systems and Tests
6.4.1. ApoStream® Technology and ApoStream® CTC Test (ApoCell)
6.4.1.1. Overview
6.4.1.2. Results
6.4.1.3. Collaborations
6.4.1.4. Funding
6.4.2. BioFluidica CTC Isolation Technology and CTC Analysis System (BioFluidica/Roche)
6.4.2.1. Overview
6.4.3.2. Results
6.4.3.3. Collaborations
6.4.3. CELLSEARCH® System and CELLSEARCH® CTC Test (Janssen Diagnostics)
6.4.3.1. Overview
6.4.3.2. Results
6.4.3.3. Collaborations
6.4.3.4. Other Developments
6.4.4. LiquidBiopsy® Rare Cell Isolation Platform and ClearID Test (Cynvenio Biosystems)
6.4.4.1. Overview
6.4.4.2. Collaborations
6.4.4.3. Other Developments
6.4.4.4. Funding
6.4.5. Parsortix System (ANGLE)
6.4.5.1. Overview
6.4.5.2. Results
6.4.5.3. Collaborations
6.4.5.4. Funding
6.4.6. QuantiGene® ViewRNA CTC Platform and Assay (Affymetrix)
6.4.6.1. Overview
6.4.6.2. Collaborations
6.4.7. IVDxTx Platform Technology and IVD CTC Assays (IVDiagnostics)
6.4.7.1. Overview
6.4.7.2. Collaborations
6.4.7.3. Other Developments
6.4.7.4. Funding
6.4.8. iCellate® (iCellate AB)
6.4.8.1. Overview
6.4.8.2. Collaborations
6.5. Liquid Biopsy and Companion Diagnostic Products
6.5.1. Tokai Pharmaceuticals and Qiagen
6.5.2. AstraZeneca and Qiagen
6.5.3. Sysmex Inostics and Bayer HealthCare
7. OTHER NOVEL NON-INVASIVE TECHNOLOGIES
7.1. Chapter Overview
7.2. Imaging Based Diagnostics
7.3. Biomarker and Nucleosome Detection
7.4. Skin Lesion Based Diagnosis
7.5. Diagnostic Breath Testing
8. MARKET SIZING AND FORECAST
8.1. Chapter Overview
8.2. Methodology
8.3. Overall Non-Invasive Cancer Diagnostic Market
8.4. Liquid Biopsy Market
8.4.1. Initial Diagnosis
8.4.2. Recurrence Monitoring
8.4.3. Patient Monitoring
8.4.4. Market Forecast Projections, 2015-2030
8.5. Opportunity Analysis for Important Indications
8.5.1. Prostate Cancer
8.5.2. Breast Cancer
8.5.3. Colorectal Cancer
8.5.4. Lung Cancer
8.6. Non-Invasive Cancer Diagnostics Market: Regional Distribution
9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Companies with Focus on Liquid Biopsy
9.2.1. Biocept
9.2.1.1. Company Overview
9.2.1.2. Financial Performance
9.2.1.3. Product Portfolio
9.2.1.4. Collaborations
9.2.2. Exosome Diagnostics
9.2.2.1. Company Overview
9.2.2.2. Product Portfolio
9.2.2.3. Collaborations
9.2.4. Genomic Health
9.2.4.1. Company Overview
9.2.4.2. Financial Performance
9.2.4.3. Product Portfolio
9.2.4.4. Collaborations
9.2.5. Guardant Health
9.2.5.1. Company Overview
9.2.5.2. Product Portfolio
9.2.5.3. Collaborations
9.2.6. Qiagen
9.2.6.1. Company Overview
9.2.6.2. Financial Performance
9.2.6.3. Product Portfolio
9.2.6.4. Collaborations
9.2.7. Trovagene
9.2.7.1. Company Overview
9.2.7.2. Financial Performance
9.2.7.3. Product Portfolio
9.2.7.4. Collaborations
9.3. Companies with Focus on Other Non-Invasive Diagnostic Techniques
9.3.1. bioMérieux
9.3.1.1. Company Overview
9.3.1.2. Financial Performance
9.3.1.3. Product Portfolio
9.3.1.4. Collaborations
9.3.2. Cepheid
9.3.2.1. Company Overview
9.3.2.2. Financial Performance
9.3.2.3. Product Portfolio
9.3.2.4. Collaborations
9.3.3. DermTech
9.3.3.1. Company Overview
9.3.3.2. Product Portfolio
9.3.3.3. Collaborations
9.3.4. DiagnoCure
9.3.4.1. Company Overview
9.3.4.2. Financial Performance
9.3.4.3. Product Portfolio
9.3.4.4. Collaborations
9.3.5. Exact Sciences
9.3.5.1. Company Overview
9.3.5.2. Financial Performance
9.3.5.3. Product Portfolio
9.3.5.4. Collaborations
9.3.7. Pacific Edge
9.3.7.1. Company Overview
9.3.7.2. Financial Performance
9.3.7.3. Product Portfolio
9.3.7.4. Collaborations
10. CONCLUSION
10.1. Improved Cancer Detection and Patient Care: A Growing Necessity
10.2. Introduction of Sophisticated Molecular Diagnostics: A Solution to the Existing Unmet Need
10.3. Liquid Biopsy: The Potential Replacement to Invasive Techniques
10.4. Other Non-Invasive Tests: Further Enhancing the Cancer Diagnostics Portfolio
10.5 With Liquid Biopsy at the Forefront, Non-Invasive Cancer Diagnostics Expected to Emerge as a Multi-Billion Dollar Market
11. INTERVIEW TRANSCRIPTS
11.1. Christer Ericsson, Chief Scientific Officer, iCellate AB
11.2. Philippe Nore, CEO and Co-founder, MiNDERA Corporation
11.3. Dr. Jake Micallef, Chief Scientific Officer, VolitionRx
12. APPENDIX 1: TABULATED DATA
13. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS
LIST OF FIGURES
Figure 3.1 Worldwide Incidence: Distribution by Type of Cancer
Figure 3.2 Lung Cancer: Estimated New Cases in 2015 (in’000s)
Figure 3.3 Breast Cancer: Estimated New Cases in 2015 (in ‘000s)
Figure 3.4 Colorectal Cancer: Estimated New Cases in 2015 (in ‘000s)
Figure 3.5 Factors Determining Useful Cancer Screening
Figure 3.6 Conventional Cancer Diagnosis Methods
Figure 3.7 Needle Biopsy and Open Biopsy: Demerits
Figure 4.1 Broad Categories of Non-Invasive Cancer Screening and Diagnostics
Figure 4.2 Types of Diagnostic Imaging
Figure 4.3 Types of Screening Assays
Figure 4.4 Types of Advanced Non-Invasive Approaches
Figure 5.1 Liquid Biopsy: Distribution by Type of Analysis
Figure 5.2 Liquid Biopsy: Distribution by Sample Source
Figure 5.3 Liquid Biopsy: Distribution by Indication
Figure 5.4 Liquid Biopsy: Distribution by Region
Figure 5.5 Other Non-Invasive Tests: Distribution by Sample Source
Figure 5.6 Other Non-Invasive Tests: Distribution by Indication
Figure 5.7 Other Non-Invasive Tests: Distribution by Region
Figure 6.1 Circulating Biomarkers for Cancer
Figure 6.2 ApoStream® Technology: Advantages
Figure 6.3 BioFluidica CTC Isolation System Workflow
Figure 6.4 BioFluidica System: Advantages
Figure 6.5 CELLSEARCH® System: Basic Steps
Figure 6.6 CELLSEARCH® System Workflow
Figure 6.7 LiquidBiopsy® Workflow
Figure 6.8 LiquidBiopsy® and Ion Torrent PGM Workflow Components
Figure 6.9 Parsortix System Workflow
Figure 6.10 ViewRNA CTC Platform Workflow
Figure 6.11 iCellate® Workflow
Figure 8.1 Non-Invasive Cancer Diagnostic Market (USD Million), Short Term, Base Case, 2015-2022
Figure 8.2 Non-Invasive Cancer Diagnostic Market (USD Million), Mid-Long Term, Base Case, 2022-2030
Figure 8.3 Liquid Biopsy Market (USD Million), Short Term, Base Case, 2015-2022
Figure 8.4 Liquid Biopsy Market (USD Million), Mid-Long Term, Base Case, 2022-2030
Figure 8.5 Prostate Cancer Liquid Biopsy Market (USD Million)
Figure 8.6 Breast Cancer Liquid Biopsy Market (USD Million)
Figure 8.7 Colorectal Cancer Liquid Biopsy Market (USD Million)
Figure 8.8 Lung Cancer Liquid Biopsy Market (USD Million)
Figure 8.9 Non-Invasive Cancer Diagnostics Market: Regional Analysis, 2022
Figure 8.10 Non-Invasive Cancer Diagnostics Market: Regional Analysis, 2030
Figure 9.1 Biocept Revenues, 2012- H1 2015 (USD Million)
Figure 9.2 Genomic Health Revenues, 2010- H1 2015 (USD Million)
Figure 9.3 Qiagen Revenues, 2010-Q1 2015 (USD Billion)
Figure 9.4 Qiagen Revenues, Q1 2015, Distribution by Business Segments (Share in %)
Figure 9.5 Trovagene Revenues, 2010-Q1 2015 (USD Million)
Figure 9.6 bioMérieux Revenues, 2011-Q1 2015 (EUR Billion)
Figure 9.7 bioNexia® FOB versus Guaiac Based Tests: Sensitivity for Positive Results
Figure 9.8 Cepheid Revenues, 2010- H1 2015 (USD Million)
Figure 9.9 Cepheid Revenues: Distribution by Type of Sales, 2014 (USD Million)
Figure 9.10 DiagnoCure Revenues, 2010-H1 2015 (USD Million)
Figure 9.11 Exact Sciences Revenues, 2010-HI 2015 (USD Million)
Figure 9.12 Pacific Edge Revenues, 2010-2014 (USD Million)
Figure 9.13 Cxbladder®: Biomarker Genes
Figure 10.1 Non-Invasive Cancer Diagnostic Market (USD Million), 2015, 2022 and 2030
LIST OF TABLES
Table 3.1 Survival on Early Diagnosis of Cancer
Table 3.2 Cost of Biopsy for Different Cancer Indications
Table 3.3 Common Endoscopic Procedures
Table 4.1 Examples of Tumour Markers
Table 5.1 Non-Invasive Cancer Diagnostics: Liquid Biopsy Tests
Table 5.2 Non-Invasive Cancer Diagnostics: Liquid Biopsy Technologies
Table 5.3 Non-Invasive Cancer Diagnostics: Liquid Biopsy Systems/ Instruments
Table 5.4 Non-Invasive Cancer Diagnostics: Other Screening and Diagnostic Tests
Table 6.1 Aspects of Biopsies versus Liquid Biopsies
Table 6.2 Liquid Biopsy Based Diagnostics: Example List
Table 6.3 Comparison between ApoStream CTC Test and CELLSEARCH® CTC Test
Table 6.4 ApoCell: Funding Instances
Table 6.5 Comparison of the Clinical Sensitivity of BioFluidica Technology and CELLSEARCH® Technology
Table 6.6 CELLSEARCH® CTC Test: Cut-offs For Disease Prognosis
Table 6.7 Cynvenio Biosystems: Funding Rounds
Table 6.8 ANGLE: Funding Rounds
Table 6.9 IVD CTC Tests: Potential Indications
Table 6.10 IVDiagnostics: Funding Rounds
Table 7.1 Sensitivity/Specificity: Individual Technologies versus Combination
Table 7.2 Imaging Based Diagnostics: Example List
Table 7.3 Biomarker and Nucleosome Detection Based Diagnostics: Example List
Table 7.4 Skin Lesion Based Diagnostics: Example List
Table 7.5 Diagnostic Breath Testing Devices: Example List
Table 8.1 Liquid Biopsy for Initial Diagnosis: Market Forecast Assumptions
Table 8.2 Liquid Biopsy for Recurrence Monitoring: Market Forecast Assumptions
Table 8.3 Liquid Biopsy for Patient Monitoring: Market Forecast Assumptions
Table 9.1 Q1Aamp® Circulating Nucleic Acid Kit: Specifications
Table 9.2 VIDAS® Tumour Markers: Specifications
Table 9.3 VIDAS® Tumour Markers, 2011-2014
Table 9.4 Xpert® HPV: Comparative Clinical Performance
Table 9.5 ImmunoCyt™/uCYT+™: Comparison with Other Urinary Cancer Biomarker Assays
Table 9.6 PCA3 Test: Launch Years for Respective Geographies
Table 12.1 Worldwide Incidence: Distribution by Type of Cancer
Table 12.2 Lung Cancer: Estimated New Cases in 2015 (in ‘000s)
Table 12.3 Breast Cancer: Estimated New Cases in 2015 (in ‘000s)
Table 12.4 Colorectal Cancer: Estimated New Cases in 2015 (in ‘000s)
Table 12.5 Liquid Biopsy: Distribution by Type of Analysis
Table 12.6 Liquid Biopsy: Distribution by Sample Source
Table 12.7 Liquid Biopsy: Distribution by Indication
Table 12.8 Liquid Biopsy: Distribution by Region
Table 12.9 Other Non-Invasive Diagnostic Tests: Distribution by Sample Source
Table 12.10 Other Non-Invasive Diagnostic Tests: Distribution by Indication
Table 12.11 Other Non-Invasive Diagnostic Tests: Distribution by Region
Table 12.12 Non-Invasive Cancer Diagnostic Market (USD Million), Short Term, Base Case, 2015-2022
Table 12.13 Non-Invasive Cancer Diagnostic Market (USD Million), Mid-Long Term, Base Case, 2022-2030
Table 12.14 Non-Invasive Cancer Diagnostic Market (USD Million), Short Term, Optimistic Case, 2015-2022
Table 12.15 Non-Invasive Cancer Diagnostic Market (USD Million), Mid-Long Term, Optimistic Case, 2022-2030
Table 12.16 Non-Invasive Cancer Diagnostic Market (USD Million), Short Term, Conservative Case, 2015-2022
Table 12.17 Non-Invasive Cancer Diagnostic Market (USD Million), Mid-Long Term Conservative Case, 2022-2030
Table 12.18 Liquid Biopsy Market (USD Million), Short Term, Base Case, 2015-2022
Table 12.19 Liquid Biopsy Market (USD Million), Mid-Long Term, Base Case, 2022-2030
Table 12.20 Liquid Biopsy Market (USD Million), Short Term, Optimistic Case, 2015-2022
Table 12.21 Liquid Biopsy Market (USD Million), Mid-Long Term, Optimistic Case, 2022-2030
Table 12.22 Liquid Biopsy Market (USD Million), Short Term, Conservative Case, 2015-2022
Table 12.23 Liquid Biopsy Market (USD Million), Mid Long Term, Conservative Case, 2022-2030
Table 12.24 Prostate Cancer Liquid Biopsy Market (USD Million)
Table 12.25 Breast Cancer Liquid Biopsy Market (USD Million)
Table 12.26 Colorectal Cancer Liquid Biopsy Market (USD Million)
Table 12.27 Lung Cancer Liquid Biopsy Market (USD Million)
Table 12.28 Non-Invasive Cancer Diagnostics Market: Regional Analysis, 2022
Table 12.29 Non-Invasive Cancer Diagnostics Market: Regional Analysis, 2030
Table 12.30 Biocept Revenues, 2012- H1 2015 (USD Million)
Table 12.31 Genomic Health Revenues, 2010- H1 2015 (USD Million)
Table 12.32 Qiagen Revenues, 2010-Q1 2015 (USD Billion)
Table 12.33 Qiagen Revenues, Q1 2015, Split by Business Segments (Share in %)
Table 12.34 Trovagene Revenues, 2010-Q1 2015 (USD Million)
Table 12.35 bioMérieux Revenues, 2011-Q1 2015 (EUR Billion)
Table 12.36 bioNexia® FOB versus Guaiac Based Tests: Sensitivity for Positive Results
Table 12.37 Cepheid Revenues, 2010- H1 2015 (USD Million)
Table 12.38 Cepheid Revenues: Distribution by Type of Sales, 2014 (USD Million)
Table 12.39 DiagnoCure Revenues, 2010-H1 2015 (USD Million)
Table 12.40 Exact Sciences Revenues, 2010-HI 2015 (USD Million)
Table 12.41 Pacific Edge Revenues, 2010-2014 (USD Million)
Table 12.42 Lung Cancer Liquid Biopsy Market (USD Million), 2015, 2022, 2030

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report